Pharmaceuticals Market Survey Report: 2016

Monday, 9 May 2016

Chinese Medical Devices Market to Grow Substantially at 20.6% of CAGR From 2015-2025: Radiant Insights, Inc

Our latest pharmaceutical market report – ‘The Chinese Medical Devices Market to 2025’ covers pharmaceutical, commercial and strategic developments in the Chinese Medical Devices Market across the next decade. We discuss key markets, key products and how the Chinese Medical Device market operates in general;

Chinese Healthcare spending has risen from $90.8bn in 2004 to reach $590.2bn across 2014, a ten-year CAGR of 20.6%. With increased governmental spend on healthcare, and increasing levels of income for many Chinese citizens, healthcare spend per capita’ is also expected to increase significantly across 2015-2025.

Key growth drivers highlighted within ‘The Chinese Medical Devices Market to 2025’ include; growing customer base, in terms of both increased population and increased numbers of health centres; expanding health insurance; a considerable geriatric population (200m people) and increased incidences of ‘lifestyle’ / non-communicable diseases.

Browse Full Report With TOC @http://www.radiantinsights.com/research/the-chinese-medical-devices-market

Key restraints in the Chinese Medical devices market include; a fragmented distribution network, that mean that the majority of foreign (non-Chinese) market entrants have had to acquire an existing Chinese medical device manufacturer to gain full market accessibility; variable intellectual property rights /patent protection laws; and differing reimbursement policies.

The Chinese Medical Devices Market to 2025’ report concludes with the competitive landscape and Company Profiles of key market players in this market, as of 2015. The market players profiled in this report include GE Healthcare, St. Jude Medical, Medtronic, Stryker, Johnson & Johnson and Boston Scientific. This report also includes the transcript of an exclusive interview with Siemens Healthcare.

Table of Contents

Chapter 1- Executive Summary

1.1 Executive Summary

1.2 Research Methodology

Related reports by Radiant Insights:http://www.radiantinsights.com/catalog/pharmaceutical

Chapter 2 - Introduction to the China Medical Devices Market

2.1 Definition of Medical Devices in China

2.2 Classification of Medical Devices

2.3 Latest CFDA Medical Device Notifications

2.4 Certification of Medical Devices

Chapter 3 - China Medical Devices Industry Structure

3.1 Hospital / Healthcare Reforms

3.1.1 Impact on the Chinese Medical Devices Industry

3.2 Five Year Plan – Planned Investment in Infrastructure / Medical Device Technology Industry

3.3 Regulatory Structure

3.3.1 Regulatory Authorities

3.3.2 Current Regulatory Policies for Medical Devices

3.3.2.1 Latest Updates – Fast Track Approval Process

3.3.3 Intellectual Property Rights / Patent Law

3.3.3.1 Latest Updates – IPR / Patent Law

3.3.4 Pricing & Reimbursement

3.3.4.1 Latest Updates - Pricing & Reimbursement

3.4 Medical Devices – Imports

3.5 Medical Devices – Exports

3.6 Distribution Channels

3.6.1 Local Distributors

3.6.2 National Distributors

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights

Contact:Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog URL: http://www.radiantinsightsinc.blogspot.com

Antidiabetics Market is expected to reach USD 84.13 billion by 2020: Radiant Insights, Inc

Global antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing prevalence of diabetes is the primary driver of this market. Growth in prevalence of disease causing lifestyle disorders such as irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. Introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Further key findings from the study suggest:

Long acting insulin was the leading product segment in 2013 and is expected to grow at the CAGR of over 15.0% during the forecast period. The introduction of advanced products, high prices associated with these products and the phasing out of human insulin are some key factors attributing for its large share.

Read Complete Report with TOC @http://www.radiantinsights.com/research/antidiabetics-market-analysis-by-product-insulin-biguanides-thiazolodinediones-glp-agonists-sulphonylureas-dpp-4-inhibitors-sglt-2-alpha-glucosidase-inhibitors-meglitinides-and-segment-forecasts-to-2020

Rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina and Onglyza on account of their once daily dosage regimens and safety profiles catalyzed the growth of this market.

North America was the most matured antidiabetics market in 2013 accounting for over 43.0% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.

Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.

Some key market players of antidiabetics include Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics and Pfizer.

Read Sample report of this Category:http://www.radiantinsights.com/catalog/pharmaceutical

The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Table of Contents

Chapter 1. Executive Summary

1.1. Antidiabetics- Industry Summary and Critical Success Factors (CSFs)

Chapter 2. Antidiabetics Industry Outlook

2.1. Market Segmentation

2.2. Market size and growth prospects

2.3. Antidiabetics - Market dynamics

2.3.1. Market driver analysis

2.3.1.1 Growing prevalence of diabetes

2.3.1.2 Presence of a strong product pipeline portfolio

2.3.1.3 Growing prevalence of lifestyle induced disorders such as obesity

2.3.2. Market Restraint Analysis

2.3.2.1. High insulin price

2.4. Key Opportunities Prioritized

2.5. Industry Analysis - Porter's

2.6. Antidiabetics - PESTEL analysis

2.7. Antidiabetics market - Pipeline overview

Chapter 3. Antidiabetics Product Outlook

3.1. Antidiabetics market share by product, 2013 & 2020

3.2. Insulin

3.2.1. Insulin market share, by product, 2013 & 2020

3.2.2. Rapid acting analog market

3.2.2.1. Rapid acting analog market, 2012 - 2020 (USD Million)

3.2.3. Long acting analog market

About Radiant Insights

For More Information, Visit Radiant Insights

Contact:Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

Thursday, 5 May 2016

PoC Lipid Test Market is expected to reach USD 280.02 million by 2022: Radiant Insights, Inc

Global Point of care (PoC) Lipid Test market is expected to reach USD 280.02 million by 2022 according to a new report by Grand View Research Inc. Growing geriatric population base, increasing global prevalence of cardiovascular diseases, and rising healthcare awareness due to patient education are the driving forces for the PoC Lipid Test industry growth during the forecast period.

Furthermore, continuous efforts by the government to reduce hospital stays and curb healthcare expenditure, establishments attempting to provide effective and rapid diagnostic results, and improvement in technology with the provision of cheap and high-quality medical solutions aimed at achieving lab automation are some factors contributing to the growth of the PoC Lipid Test market.

Further key findings from the study suggest:

Alere Cholestech LDx market was estimated at over 6,400 units in 2014 and is expected to reach over 11,000 units by 2022, growing at a CAGR of 7.8% over the forecast period. The analyzer is included in the CLIA waived test list and is certified by the Cholesterol Reference Method Laboratory Method Network (CRMLN) program and Lipid Standardization Program (LSP)

Browse Full Report With TOC @http://www.radiantinsights.com/research/point-of-care-poc-lipid-test-market

Global launch of Roche Cobas b 101 at the end of 2013 excluding the U.S. region and the introduction of Samsung LABGEO PT10 in the Indian market are expected to drive the point of care Lipid Test market at a lucrative rate over the next six years

Consumables Piccolo Express by Abaxis market was valued over 1,000 thousand units in 2014 owing to the presence of CLIA-waived capillary or venous lipid and liver panel used for monitoring statin medications results. Abaxis is the only company, which provides a venous or capillary or CLIA waived Lipid and Liver panel.

Hyperlipidemia is the largest application area for PoC Lipid Test industry with revenue of over USD 55 million in 2014. Whereas, hypertriglyceridemia is the fastest growing application area with the expected growth rate of 5.6% during the forecast period due to increasing incidences of hypertriglyceridemia and the introduction of technologically advanced products such as CardioChek PA by PTS Diagnostics.

Europe constituted the largest share of over 35% in 2014 of the total market. Presence of favorable regulations and initiatives pertaining to the development of healthcare infrastructure, and also high disease prevalence levels in the region are the major factors responsible for its growth

Read Sample report of this Category:http://www.radiantinsights.com/catalog/biotechnology

Asia Pacific accounted for over 19% share in 2014 of the total market. However, the market share of this region is estimated to increase at a CAGR of 5.8% by 2022 due to increasing demand for rapid diagnostic testing in developing countries such as India and China.

Some key players of this market include Abaxis Inc., Roche Diagnostics, Alere Inc., Polymer Technology Systems (PTS Diagnostics), and Samsung Electronics Corporation. Alere with its product portfolio including Alere Cholestech LDx and Alere Afinion AS100 Analyzer was the leader in the POC lipid testing market with a share of over 22% in 2014

Table of Contents

Chapter 1 Methodology and Scope

1.1 Research Methodology

1.2 Research Scope & Assumptions

1.3 List of Data Sources

Chapter 2 Executive Summary

Chapter 3 PoC Lipid Test Industry Outlook

3.1 Market segmentation

3.2 Market size and growth prospects

3.3 PoC Lipid Test: Market dynamics

3.3.1 Market Driver Analysis

3.3.2 Market Restraint Analysis

3.5 Industry analysis Porter's

3.6 PoC lipid testing company market share/competitive landscape, 2013

3.7 PoC Lipid Test: PESTEL Analysis

3.8 Examples CLIA waived tests for Lipid Testing

3.9 PoC Lipid Test Market: Product Positioning, by Instrument, 2014 (based on application, regional presence and strategic initiatives)

About Radiant Insights

For More Information, Visit Radiant Insights

High Throughput Screening Market To Witness Enhanced Demand In technology and product segments of HTS in biotechnology and pharmaceutical application sector at Radiant Insights, Inc

This report on High Throughput Screening (HTS) emphasizes on both the technology and product segments of HTS in biotechnology and pharmaceutical application areas. The major technologies analyzed include Ultra High Throughput Screening, High Content Screening, Bioinformatics and Microfluidics/Lab-On-a-Chip; and the major product segments encompass HTS Services and HTS Tools. The global markets for Novel High Throughput Screening Products and Cell Based Assays are also discussed in the report. Markets covered for Microfluidics and Bioinformatics pertain to the applications of HTS. The report provides essential information including market data, segmentation, market size, key trends, M&A, product developments, industry forecasts, corporate intelligence, and other relevant information. The report lists more than 600 companies that are engaged in HTS services and/or production of HTS tools/instruments. Major Contract Research Organizations serving HTS industry are also covered in the corporate directory section of this report. Estimations and predictions are graphically represented by region, by technology and by product segment. Compilation of Worldwide Patents and Research related to High Throughput Screening is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific and Rest of World. The market is analyzed in US Dollars and includes 123 exclusive exhibits.

View summary of this report @http://www.radiantinsights.com/research/high-throughput-screening

Table of Content

I. SCOPE AND METHODOLOGY 1

II. REPORT SYNOPSIS 3

Foreword 3

Technology and Product Segmentation 4

Exhibit 1. Segmentation of Global HTS Market by Technology and Product Segments 4

Global Market Analysis 5

Exhibit 2. High Throughput Screening – Global Market Estimations and Predictions (2005-2020) in US$ Billion 5

Exhibit 3. List of Major Global HTS Companies 6

Download sample Copy of This Report at:www.radiantinsights.com/research/high-throughput-screening#tabs-4

III. MARKET DYNAMICS 8

Industry Overview 8

Market Overview 8

Global HTS Market 8

Exhibit 4. High Throughput Screening – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific and Rest of World in US$ Million 9

Exhibit 5. High Throughput Screening – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World 10

Novel High Throughput Screening Products Market 11

Exhibit 6. Novel High Throughput Products – Global Market Estimations and Predictions (2005-2020) in US$ Million 11

Cell Based Assays Market 12

Exhibit 7. Cell-Based Assays – Global Market Estimations and Predictions (2005 - 2020) in US$ Million 12

Major Global Players in Cell based Assays Market 13

Exhibit 8. Global Market for Cell based Assays (2004 & 2005): Percentage Breakdown of Market Shares for GE Healthcare, PerkinElmer, BD Biosciences, Beckman Coulter, Invitrogen, Molecular Devices and Other 13

North American HTS Market 14

Exhibit 9. High Throughput Screening – North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million 14

Exhibit 10. High Throughput Screening – North American Market Shares by Country (2010, 2015 & 2020) for United States and Canada 15

Exhibit 11. List of Major Companies in North America 15

United States HTS Market 16

Canadian HTS Market 16

European HTS Market 17

About Radiant Insights

For More Information, Visit Radiant Insights

Biodefense Market is expected to reach USD 13.33 billion by 2020: Radiant Insights, Inc

Global biodefense market is expected to reach USD 13.33 billion by 2020. Growing R&D investments in the field of biotechnology coupled with increasing threat of bioterrorism and disease outbreaks is expected to drive market growth during the forecast period. Furthermore, presence of favorable government initiatives for instance the Emergency Use Authorization (EUA) is expected to boost market growth. This provision allows products to be marketed without an FDA approval in an emergency. Initiatives undertaken by the governments of developing nations for strengthening their respective biodefense product portfolio is expected to fuel future market growth.

Biodefense against anthrax accounted for the largest market share owing to its inclusion in the class A highest priority pathogen category. This classification has resulted in the presence of extensive R&D investments aimed at new product development for strengthening national stockpiles. The global biodefense against anthrax was valued at over USD 2.0 billion in 2013.

Access This Full Report @http://www.radiantinsights.com/research/biodefense-market-analysis-by-product-anthrax-smallpox-botulism-radiation-nuclear-ebola-hemorrhagic-fever-and-segment-forecasts-to-2020

Further key findings from the study suggest:

North American was the most revenue generating region in 2013. Majority of the funding programs are organized by the U.S. based government and private establishments. Moreover, these establishments cater to procurement needs of foreign markets.

The market is majorly governed by the initiatives undertaken in the U.S. The country is the largest revenue contributor and is expected to maintain its market position throughout the forecast period. Moreover, funding received by manufacturers under projects such as BioShield is expected to significantly boost demand over the next six years.

Developed European countries such as Germany and the UK have designated funding policies in place pertaining to biodefense. In Switzerland, there is no set biodefense definition but the NBC (nuclear, biological, chemical) protection and research is carried out in Spiez Laboratory of Federal office for Civil Protection, within the Federal Department of Defense. A total of 12 civilian facilities operate under the Swiss biodefense program.

Key players of this market include Emergent BioSolutions, SIGA Technologies, Xoma Corporation and PharmAthene.

Related reports by Radiant Insights:http://www.radiantinsights.com/catalog/pharmaceutical

Mergers and acquisitions and participating in government tenders are two key sustainability strategies adopted by market players. For instance, in December, 2014, Emergent BioSolutions announced that it had acquired the EV-035 series of molecules from Evolva Holding SA. The acquisition will further strengthen the company's biodefense line of products.

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Biodefense Industry Outlook

2.1 Market Segmentation

2.2 Market size and growth prospects

2.3 Biodefense - Market dynamics

2.3.1 Market driver analysis

2.3.1.1 Presence of favorable government initiatives

2.3.1.1.1 Emergency Use Authorization of Medical Products

2.3.1.1.2 Project BioShield Act

2.3.2 Market Restraint Analysis

2.3.2.1 Low market penetration in developing and underdeveloped countries

2.4 Key Opportunities Prioritized

2.6 Biodefense - PESTEL analysis

2.7 Market scenario by type

2.7.1 Biological Defense

2.7.2 Chemical Defense

2.7.2.1 Chemical defense: Product pipeline

2.7.3 Nuclear/Radiological Defense

2.7.3.1 Nuclear/radiological defense: Product pipeline analysis

About Radiant Insights

For More Information, Visit Radiant Insights

Wednesday, 4 May 2016

Home Infusion Therapy Market is expected to reach USD 31.9 billion by 2022: Radiant Insights, Inc

Global Home Infusion Therapy Market is expected to reach USD 31.9 billion by 2022, according to a new study by Grand View Research Inc. Rising incidence of chronic disorders has led to an augmentation in the demand for infusion therapy in outpatient settings, thereby boosting the home infusion therapy market. Rapidly growing geriatric population base globally, is also likely to serve this market as a high impact rendering driver. The home infusion therapy is considered beneficial for patients as they get the entire treatment at the comfort of their home. Furthermore, home infusion therapy is a cost effective alternative to placement in hospital, and allows patients to adhere to their normal lifestyle while receiving treatment. Rising incidences of hospital acquired infections is a high impact rendering driver of this market. Additional healthcare spending associated with these infections are expected to encourage patients to prefer home care over the conventional settings.

Further key findings from the study suggest:

Needleless connectors are expected to witness lucrative growth over the forecast period. Growing demand for enhanced healthcare service provider safety has led to the rise in demand for needleless connectors.

To Get Full Report Click Here @http://www.radiantinsights.com/research/home-infusion-therapy-market

Anti-Infective dominated the market with a revenue share of over 25.0% in 2014. Home administration of anti-infective therapy is preferred by patients who have chronic infections that cannot be treated through oral agents. It is considered as the most user friendly home infusion therapy.

North America accounted for more than 40% of the home infusion therapy market in 2014 on account of the presence of large geriatric population base. Presence of sophisticated healthcare infrastructure and favorable reimbursement plans laid out by regulatory bodies are also expected to make significant contributions towards market growth.

Asia Pacific is expected to emerge as a high growth market over the forecast period. Presence of large unmet needs in the emerging economies such as China and India. Rising patient awareness levels regarding the benefits of home infusion therapies over the in-hospital infusion therapies is expected to further boost the growth of this region.

Read Sample report of this Category:http://www.radiantinsights.com/catalog/medical-devices

Key players of home infusion therapy market include B. Braun Melsungen AG, Fresenius Kabi AG, Baxter, CareFusion Corporation and Hospira Inc. Mergers and acquisitions and entering into strategic collaborations with healthcare providers are two key sustainability strategies adopted by these market participants.

Table of Contents

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumption

1.3. List of Data Sources

Chapter 2. Executive Summary

2.1. Home Infusion Therapy - Industry Summary and Key Buying Criteria, 2012 - 2022

Chapter 3. Home Infusion Therapy Industry Outlook

3.1. Home infusion therapy market segmentation

3.2. Home infusion therapy market size and growth prospects

3.3. Home infusion therapy market dynamics

3.3.1. Market driver analysis

3.3.2. Market restraint analysis

3.4. Key opportunities prioritized

3.5. Industry analysis - Porter's

3.6. Home infusion therapy market PESTEL analysis, 2014

3.7. Home infusion therapy - Unmet need analysis

Chapter 4. Home Infusion Therapy Product Outlook

4.1. Home infusion therapy market share by product, 2014 & 2022

4.2. Infusion pumps

4.2.1. Infusion pumps market estimates and forecasts, 2012 - 2022 (USD Million)

4.3. Intravenous sets

4.3.1. Intravenous sets market estimates and forecasts, 2012 - 2022 (USD Million)

4.4. Needleless connectors

4.4.1. Needleless connectors market estimates and forecasts, 2012 - 2022 (USD Million)

About Radiant Insights

For More Information, Visit Radiant Insights

Contact:Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com